Bacteriophage T4 Life Cycle: 3D Animation of E. coli Infection

Bacteria evolved defense mechanisms against viral infection including receptor reduction, polysaccharide coat secretion, and restriction-modification systems that cleave foreign DNA. The CRISPR-Cas system provides adaptive immunity: during adaptation, foreign DNA is cleaved into protospacers and incorporated into the CRISPR array; during interference, these spacers guide Cas proteins to recognize and cleave matching viral DNA. This system has been adapted for gene editing technology.

Bacterial restriction-modification systems protect against viral DNA by methylating bacterial DNA and cutting unmethylated viral DNA. CRISPR spacers are acquired from viral DNA upon first infection, creating a memory of encountered viruses. This adaptive immunity allows bacteria to recognize and destroy specific viruses upon re-infection, analogous to vertebrate adaptive immunity.

Restriction enzymes evolved as bacterial defense mechanisms against viral invaders (phages). When phages infect bacteria, they deliver their genomes to degrade the bacterial chromosome. In response, bacteria produce restriction enzymes that identify and cleave foreign DNA. However, bacteria face a dilemma: these same enzymes could accidentally destroy the bacterial genome. To solve this, bacteria developed a complementary system using methyltransferases that modify their own DNA with methyl groups, creating molecular tags that signal restriction enzymes not to cleave self-DNA. This restriction-modification system provides bacteria with adaptive immunity against viral infections while protecting their own genetic material.

Bacteria employ multiple defense strategies against phage infection. Prevention of adsorption includes receptor modification, biofilm formation, capsule secretion, and phase variation. Upon successful infection, bacteria activate restriction-modification systems that cleave foreign DNA, CRISPR-Cas systems that provide adaptive immunity, and abortive immune systems that kill infected cells to prevent phage propagation. These systems work at different stages of infection and provide layered protection. The restriction-modification system is the most common, while CRISPR-Cas provides adaptive immunity that can be inherited by daughter cells.

Bacteria face constant viral infection pressure from bacteriophages, which are the most abundant entities on Earth (10 times more than bacteria). Bacteria have evolved two main immune arms: CRISPR-Cas provides adaptive immunity by memorizing past infections through stored viral DNA fragments that block future infections; restriction-modification systems provide innate immunity using restriction enzymes that cleave foreign DNA while modification enzymes protect bacterial DNA. These systems represent fundamental strategies that bacteria use to survive in environments teeming with viruses.

Phage therapy uses bacteriophages as alternatives to antibiotics for treating bacterial infections, particularly antibiotic-resistant bacteria. Phages have high specificity for their target bacteria, minimizing effects on beneficial microbiota. Current applications include treatment of multidrug-resistant infections, with ongoing clinical trials for cystic fibrosis and multidrug-resistant urinary tract infections. A documented case involved a patient with multidrug-resistant Pseudomonas infection who was cured using phage therapy after failing all antibiotics. Phage therapy represents an emerging approach to combat antibiotic resistance, though it carries risks due to viral mutation potential and requires careful monitoring.

Bacteriophages are viruses that specifically target and kill bacteria by attaching to bacterial cells, injecting their DNA, replicating within the bacteria, and lysing the cell every 22 minutes; unlike broad-spectrum antibiotics that disrupt the entire human microbiome, phages are highly species-specific and can effectively combat antibiotic-resistant bacteria such as Pseudomonas and MRSA, with clinical trials showing significant reductions in bacterial loads (up to two-log reductions) in patients with cystic fibrosis and complicated bacteremia, suggesting phage therapy could serve as either a standalone or complementary treatment to antibiotics for severe resistant infections.

Bacteriophages are viruses that specifically target and destroy certain bacteria; this experimental therapy has shown promise for treating multidrug-resistant bacterial infections when conventional antibiotics fail, as demonstrated by a successful case at UC San Diego where an international team identified and deployed phages against a patient's unique bacterial isolate, leading to rapid recovery.

Antibiotic resistance is a global health crisis, with approximately 700,000 deaths annually from antibiotic-resistant infections. This has prompted renewed interest in phage therapy as an alternative treatment. In 2016, the first successful intravenous phage therapy case in the United States was reported, treating a patient with a severe multidrug-resistant infection. In 2018, a 15-year-old cystic fibrosis patient was successfully treated with a combination of natural and genetically modified phages. Western medical communities, particularly American infectious disease specialists, are increasingly recognizing phage therapy as an important alternative or complement to antibiotics. The high specificity of phages for their bacterial hosts allows precise targeting without disrupting the rest of the microbiome, though this specificity also creates challenges for developing broad-spectrum treatments.

Phage therapy uses viruses that specifically infect and destroy bacteria to treat antibiotic-resistant infections; unlike broad-spectrum antibiotics, phages are highly targeted, making them promising alternatives for patients who have exhausted conventional treatments and face life-threatening drug-resistant bacterial infections.

Bacterial transduction is a horizontal gene transfer mechanism where bacteriophages (viruses that infect bacteria) transfer bacterial genes between cells. It occurs through two mechanisms: generalized transduction during the lytic cycle, where random bacterial DNA fragments are accidentally packaged into viral particles and transferred to new hosts; and specialized transduction during the lysogenic cycle, where improper excision of the viral genome carries specific bacterial DNA sequences near the integration site. A key distinction from transformation is that transduction always transfers double-stranded DNA, whereas transformation involves single-stranded DNA uptake.

Generalized transduction involves lytic phages packaging random bacterial DNA fragments during viral particle assembly, allowing any gene segment to be transferred between bacteria; specialized transduction occurs when lysogenic phages accidentally package bacterial DNA adjacent to their integrated viral genome during the switch from lysogenic to lytic cycle, transferring specific bacterial gene fragments along with viral DNA.

During the lytic cycle, bacterial DNA fragmentation creates opportunities for horizontal gene transfer. General transduction occurs when random host DNA fragments become packaged into phage capsids, allowing transfer to new hosts—any genomic region can be transferred. Specialized transduction, associated with the lysogenic cycle, transfers only host DNA flanking the prophage integration site. Both mechanisms enable genetic material exchange between bacteria, contributing to bacterial evolution and antibiotic resistance spread.

Transduction is a mechanism of horizontal gene transfer mediated by bacteriophages (viruses that infect bacteria). There are two types: generalized transduction occurs when a phage accidentally packages bacterial DNA instead of its own viral DNA during the lytic cycle, and when these phages infect new bacteria, they inject bacterial DNA from the previous host. Specialized transduction occurs when a phage integrates into the bacterial chromosome (lysogenic cycle) and, upon excision, carries adjacent bacterial genes along with its own genome. Both mechanisms allow bacteria to acquire new genetic material and potentially new traits, contributing to bacterial evolution and adaptation.

Bacteriophages facilitate horizontal gene transfer between bacteria through transduction. Generalized transduction (using lytic phages like P22) occurs when bacterial DNA fragments are accidentally packaged into phage particles. When these particles infect new hosts, the bacterial DNA can recombine with the recipient's chromosome. This process is rare (1 in 100,000-1,000,000 particles) but was historically important for bacterial genetic mapping. Specialized transduction (using temperate phages) transfers only genes adjacent to the prophage integration site. This mechanism allows non-pathogenic bacteria to acquire virulence factors from pathogenic bacteria, potentially converting them into pathogens.